Dennis Kim, MD, PhD

My research is aiming to develop projects of: 1) biomarker discovery using genomics in leukemias and allogeneic stem cell transplantation; and 2) clinical research in chronic myeloid leukemia and graft-versus-host disease after allogeneic stem cell transplantation.

I have also been involved in multiple exome sequencing projects in acute myleoid leukemia (AML) with normal karyotype and secondary AML progressed from antecedent hematologic malignancies, as well as chronic myeloid leukemia (CML). My future direction of genomic research is to integrate multi-omics platforms to investigate leukemia genomes, thus dissecting clonal structures in a refined way.

Not only in translational research, but also in the clinical research field, I have shown significant progress in three ways: 1) clinical database registry; 2) retrospective studies using the database; and 3) generation of prospective clinical trials in CML and in graft-versus-host disease (GVHD) and other post-transplant complications after allogeneic stem cell transplantation.  First of all, I developed a clinical database of allogeneic transplant patients (especially for GVHD and post-transplant complications) and CML patients (especially for treatment outcomes after tyrosine kinase inhibitor therapy). Secondly, I have participated in multiple ongoing clinical retrospective studies generated from the registry database. Thirdly, I am involved in  multiple clinical trials. Currently, I am the principal investigator of a pivotal Canadian tyrosine kinase inhibitor (TKI) discontinuation clinical trial and am also a chair of the correlative part of this trial, entitled "Treatment-free Remission Accomplished with Dasatinib (TRAD)". This is the first Canadian TKI discontinutation trial for the management of CML.
Bone Marrow Transplant. 2019 Oct 14;:
Alblooshi RM, Deotare U, Michelis FV, Thyagu S, Kim DDH, Lipton JH, ElGohary GM, Viswabandya A
Eur J Haematol. 2019 Sep 23;:
Salas MQ, Atenafu EG, Bautista MR, Prem S, Lam W, Datt Law A, Shaibani ZA, Kim DDH, Michelis FV, Lipton JH, Viswabandya A, Mattsson J, Kumar R
Eur J Haematol. 2019 Sep 12;:
Salas MQ, Lam W, Law AD, Kim DDH, Michelis FV, Loach D, Al-Shaibani Z, Lipton JH, Kumar R, Mattsson J, Viswabandya A
Eur J Haematol. 2019 Nov;103(5):510-518
Salas MQ, Prem S, Atenafu EG, Law AD, Lam W, Al-Shaibani Z, Loach D, Kim DDH, Michelis FV, Lipton JH, Kumar R, Mattsson J, Viswabandya A
Eur J Haematol. 2019 Nov;103(5):483-490
Prem S, Atenafu EG, Avena J, Bautista R, Law A, Lam W, Michelis FV, Kim DDH, Viswabandya A, Lipton JH, Mattsson J, Kumar R
Eur J Haematol. 2019 Nov;103(5):519-522
Prem S, Al-Shaibani Z, Michelis FV, Kim D, Viswabandya A, Lipton JH, Kumar R, Mattsson J, Law A, Lam W
PLoS One. 2019;14(6):e0218968
Woo YM, Kim S, Park JH, Lee NY, Kim JW, Kim DDH
Leukemia. 2019 Jun 17;:
Branford S, Kim DDH, Apperley JF, Eide CA, Mustjoki S, Ong ST, Nteliopoulos G, Ernst T, Chuah C, Gambacorti-Passerini C, Mauro MJ, Druker BJ, Kim DW, Mahon FX, Cortes J, Radich JP, Hochhaus A, Hughes TP, International CML Foundation Genomics Alliance
Exp Hematol. 2019 Jun 12;:
Ahn JS, Kim T, Kim YK, Cho YC, Cho S, Jung SH, Ahn SY, Jung SY, Yang DH, Lee JJ, Choi S, Lee JY, Shin MG, Yoshida K, Ogawa S, Kim IC, Zhang Z, Kim HJ, Kim DDH
Biol Blood Marrow Transplant. 2019 Jun 04;:
Shapiro RM, Shin E, Law AD, Lam W, Michelis FV, Viswabandya A, Kumar R, Lipton JH, Messner H, Mattsson J, Kim DDH

Pages